Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension
NCT06249633Phase 1Not yet recruiting
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nitric oxide in pulmonary hypertension (PH). Primary endpoints: Pulmonary Artery Pressure at 4 days, Tricuspid Annular Plane Systolic Excursion at 4 days and 1 more. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
nitric oxide
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT06249633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06249633.